Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Indivior Pharmaceuticals Inc. Common Stock (INDV) vs Eli Lilly And Co (LLY) Price & Performance

Indivior Pharmaceuticals Inc. Common StockTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Indivior Pharmaceuticals Inc. Common Stock vs Eli Lilly And Co — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.3 (market cap $4.18B), while Eli Lilly And Co trades at $1,226 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 248.8× Indivior Pharmaceuticals Inc. Common Stock's market cap, and Eli Lilly And Co pays a 0.59% dividend while Indivior Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and Eli Lilly And Co for 94 Days on average.

INDVLLY
Market Cap
$4.18B$1.04T
Volume
1,819,7461,843,375
Sector
HealthHealth
52-Week High
$41.83$1.28K
52-Week Low
$24.09$799.57
Typical Hold Time
0 Days94 Days
Enterprise Value
$4.47B$1.09T
Dividend Yield
—0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Indivior Pharmaceuticals Inc. Common Stock

No Aura AI signal available yet.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,211.40, up 2.43% today, with a bullish technical outlook and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 surpassing the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights pipeline advancements in weight-loss drugs, including EloraTZP's promising trial results.

Outlook remains positive given dominant market position in obesity and diabetes treatments, with analyst consensus price target of $1,350 implying ~11% upside. Key risks include competitive pressures from Novo Nordisk and regulatory hurdles. Earnings growth and pipeline catalysts support further appreciation, though high valuations warrant monitoring.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INDV
100% Buy0% Sell
Avg holding period · 0 Days
LLY
20% Buy80% Sell
Avg holding period · 94 Days

Top news

Latest headlines on both assets

About Indivior Pharmaceuticals Inc. Common Stock

Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.

Read more on INDV →

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY →